209 related articles for article (PubMed ID: 36656341)
1. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.
Ehlers FAI; Mahaweni NM; van de Waterweg Berends A; Saya T; Bos GMJ; Wieten L
Cancer Immunol Immunother; 2023 Jun; 72(6):1789-1801. PubMed ID: 36656341
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
3. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
Front Immunol; 2018; 9():2140. PubMed ID: 30294328
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract][Full Text] [Related]
6. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren HG; Nahi H; Wagner AK; Alici E
Cancer Immunol Immunother; 2023 May; 72(5):1153-1167. PubMed ID: 36355079
[TBL] [Abstract][Full Text] [Related]
7. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
8. NKG2A Expression Is Not
Mahaweni NM; Ehlers FAI; Sarkar S; Janssen JWH; Tilanus MGJ; Bos GMJ; Wieten L
Front Immunol; 2018; 9():1415. PubMed ID: 29988376
[TBL] [Abstract][Full Text] [Related]
9. ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response.
Ehlers FAI; Beelen NA; van Gelder M; Evers TMJ; Smidt ML; Kooreman LFS; Bos GMJ; Wieten L
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203549
[TBL] [Abstract][Full Text] [Related]
10. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR
Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559
[TBL] [Abstract][Full Text] [Related]
12. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
Jochems C; Hodge JW; Fantini M; Tsang KY; Vandeveer AJ; Gulley JL; Schlom J
Int J Cancer; 2017 Aug; 141(3):583-593. PubMed ID: 28477372
[TBL] [Abstract][Full Text] [Related]
13. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
[TBL] [Abstract][Full Text] [Related]
15. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.
Tomescu C; Tebas P; Montaner LJ
AIDS; 2017 Mar; 31(5):613-622. PubMed ID: 28225449
[TBL] [Abstract][Full Text] [Related]
16. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
19. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
Terszowski G; Klein C; Stern M
J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
[TBL] [Abstract][Full Text] [Related]
20. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
